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ABSTRACT

Infants born below 2,500 grams are classified as low birth weight. Reduced birth weight
has been shown to increase the risk of infant mortality and chronic adulthood diseases. In 2007,
Hamilton Country reported 12.0% of live births to be low birth weight, compared to the state
average of 9.4%. An excess in utero exposure to cortisol has been linked to restricted fetal
growth.

Placental production of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2)

inactivates cortisol before passage into the fetus. This study tests the hypothesis that increased
placental 11β-HSD2 expression has a positive correlation with an individualized birth weight
centile. A Spearman's rank correlation reported a significant correlation between these two
variables (p = 0.024).

Additionally, birth weight was significantly different between

underweight and obese mothers, married vs. single mothers and black vs. white mothers. These
results reinforce the importance of proper 11β-HSD2 expression for optimal fetal growth.
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CHAPTER 1
INTRODUCTION

Birth weight carries with it strong ties to infant mortality, and also adult health.
Children born under 2500 grams places that child at a 20x greater risk for death within the first
year than a child born above that weight (Wilcox and Skjaerven, 1992). Being born on the
smaller end of the normal birth weight range carries an increased risk of adult chronic diseases,
such as heart disease and type 2 diabetes (Barker et al., 1989; Yajnik et al., 1995). Maternal
habits, such as smoking, are well known to be an influence on birth weight (Krentz et al., 2011).
Others, such as marital status, maternal body mass index, maternal age of greater than 35, and
race have shown to correlate with birth weight (David and Collins, 1997; Ehrenberg et al., 2003;
Joseph et al., 2005; Shah et al., 2011). Hamilton County, TN has an elevated rate of low birth
weight infants, when compared to other metro areas in the state, and to the national rate
(Decosimo et al., 2010). Maternal habits and socioeconomic factors cannot fully explain this
increased rate of low birth weight births, though certain community-based initiatives have been
implemented to help alleviate some of those factors (Featherstone, 2010).
One of the most recent theories to explain the mechanism of low birth weight births is
an over-exposure to cortisol in utero, which is the focus of the current study. Cortisol is a stress
hormone and is regulated by the hypothalamus (Sherwood, 2006). Localized production of
cortisol is required for proper fetal organ maturation (Speirs et al., 2004). However, an excess of
maternally derived cortisol, via passage through the placenta, has been correlated with reduced
birth

weight

and

intrauterine

growth

restriction
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(McTernan

et

al.,

2001).

The passage of maternally derived cortisol is modulated by the enzyme 11βhydroxysteroid dehydrogenase (11β-HSD) type 2, which is highly expressed in the
syncytiotrophoblast layer, where the maternal-fetal interface is located (Yang, 1997). Active
cortisol is inactivated to cortisone by this enzyme before passage into the fetal blood supply.
Local amplification of cortisol, from cortisone, is modulated by 11β-HSD type 1 and is
expressed in fetal tissues (Alfaidy et al., 2003). These isozymes (11β-HSD1 and 11β-HSD2)
work in concert with each other to ensure proper fetal development. Stymied fetal growth has
been linked in the reduction of the 11β-HSD2 placental barrier (Dy et al., 2008; McTernan et al.,
2001; Shams et al., 1998).
However, other maternal characteristics have been shown to influence birth weight (i.e.,
maternal height, maternal weight at first clinical visit, parity, ethnic group, geographical region),
as well as infant sex and gestational age (Gardosi et al., 1992). When those factors are controlled
for, a more accurate representation of the growth potential of an infant can be made, allowing for
a better detection of potentially pathogenic factors that affect fetal growth and development.
Gardosi and Francis (2009) developed such software, which takes into account the conditions
listed above, and returns a birth weight centile calculation, which is a more accurate assessment
of intrauterine conditions.
The current study investigates whether the expression of 11β-HSD2 in placenta tissue
correlates with birth weight in infants born in Hamilton County, TN. With the importance of
protecting the fetus from an excess of maternal cortisol, through the workings of the 11β-HSD2
enzyme, the current study measured the expression of this enzyme in 242 placenta samples
collected from Erlanger Hospital in Chattanooga, TN. Expression measurement was done via
quantitative reverse transcription polymerase chain reaction assay. Additional comparison were
3

made based on maternal age (less than 35 vs. 35 and up), marital status (single vs. married), prepregnancy BMI (under vs. average vs. overweight vs. obese), maternal drug use in noncomplicated pregnancies (use vs. non-use), race (Caucasian vs. African American vs. Hispanic)
and maternal education (less than high school vs. high school/GED vs. some college) to see if
these groupings had any influence on infant birth weight, 11β-HSD2 enzyme expression or the
calculated birth weight centile.
A molecular examination of the placenta, via quantification of 11β-HSD2 expression,
could be used as a means to easily assess the health and growth potential of an infant, which
could alleviate the need for more invasive procedures, such as the collection of cord blood, to
occur. The current study examines the usefulness of the placenta as a diagnostic tool in regards
to fetal health as measured by birth weight or assessment of the fetal growth potential. No
attempt was made to measure actual enzyme activity, which is the efficiency of which cortisol is
converted to cortisone. Enzyme activity is more sensitive to environmental pollutants and would
be a better end point to examine if indeed Hamilton County’s (especially Chattanooga’s southern
neighborhoods) industrial past and long lived organic compounds and/or metals have a
significant influence on the birth weight of these infants. However, since expression begets
activity, 11β-HSD2 enzyme expression is an effective measurement of the cortisol protection
that

this

enzyme
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provides.

CHAPTER 2
LITERATURE REVIEW

Hamilton County, TN and Low Birth Weight Infants
Hamilton County Tennessee has an elevated incidence of low birth weight (LBW) births,
defined as infants born below 2,500 grams. In 2007, Hamilton Country reported 12.0% of live
births as low birth weight, with the state average of 9.4% (Decosimo et al., 2010). This trend is
disproportionate among races, with the black population reporting a rate of 18.6% and the white
population at 9.7%, though both races have an elevated incidence compared to the national
average of 8.2%. Even among other metropolitan areas in the state, the low birth weight rate is
still elevated, with Shelby (Memphis), Davidson (Nashville) and Knox (Knoxville) counties
following with 11.1%, 9.3% and 8.8%, respectively. Very low birth weight (VLBW) babies
(defined as less than 1,500 g) were reported at 2.2% of live births in 2007. Again, when race is
factored into these statistics, the black population is represented disproportionally, with a rate of
almost double the white population (3.7% and 1.7%, respectively). Low birth weight is a
significant factor in infant mortality (Wilcox and Skjaerven, 1992). Hamilton County reported
9.7 deaths/1000 births, which is greater than both the national and state rates (6.8 and 8.7
deaths/1000 births respectively).
A study done by the Ochs Center for Metropolitan Studies (2010) reported an Infant
Health Risk Factor Index (IHRFI) for sub-regions of Hamilton County. This IHRFI score
considered six pregnancy outcome indicators: percentage of low birth weight births, percentage
of preterm births, percentage of delayed or no prenatal care pregnancies, percentage of births to
5

teenage mothers, percentage of births to single mothers, and percentage of births to mothers
without a high school degree. Possible scores ranged from 6, representing the lowest risk, to
216, the highest risk. Areas of Hamilton County with the greatest IHRFI were Amnicola/East
Chattanooga (zip code 37406) at 206, followed by Glenwood/Eastdale (37404/37406) at 200,
South Chattanooga (37409/37410) at 195, Bushtown/Highland Park (37404) at 194 and
Downtown (37408/37402) and Ridgedale/Oak Grove/Clifton Hills (37407) receiving the same
score of 192. In contrast, Signal Mountain (37377) received a score of 12. The full Ochs Center
for Metropolitan Studies report contains a full list of Hamilton County sub-regions and IHRFI
and LBW listings, along with additional demographic characteristics.
Community based incentives in the state of TN have been developed in order to
improve pregnancy outcomes. The BLUES (Building Lasting Unshakeable Expectations into
Successes) project started in Shelby County in 2005, with the first cohort study ending in 2009
(Kimberly Lamar, 2010). Objectives of the program included increasing pregnancy health
education and prenatal health services for low-income mothers, as well providing social support
and community outreach. This holistic approach to improving pregnancy outcomes was designed
to target minority populations, especially African Americans, where disparities in pregnancy
outcomes are widely reported. Data from the 2005-2009 cohort showed significant improvement
in low birth weight rates (9.81% in BLUES compared to 18.60% in control group, p <0.001), as
well as significant improvement in prematurity and infant deaths (p=0.0001).

Additional

expansion of this program into Hamilton County targeted specific zip codes (37410, 37408,
37406, and 37403). The Hamilton County pilot study showed an 8% drop in prematurity and
LBW, and an 11% drop in infant mortality in the BLUES subjects when compared to the county
as a whole.

6

Birth weight is a common study parameter due its abundant data sets (being a vital
population statistic) and is strong predictor for infant mortality. However, raw statistics of LBW
incidences often disregard gestational age, which is the main cause for low birth weight.
Historically, low birth weight and prematurity were used interchangeably. Consequently, a new
term, intrauterine growth restriction (IUGR), was introduced. IUGR infants are clinically full
term (>37 weeks), but still have stunted growth (10th centile for birth weigh), whereas premature
infants have not had the proper gestational length in order to achieve a healthy weight (Peleg et
al., 1998; Wilcox, 2001).

Birth Weight as a Measure of Adult Health
One of the pioneer researchers that proposed a link between birth weight and
subsequent adult cardiovascular health was David J. P. Barker. His work on this subject is
collectively known as the Barker Hypothesis (http://www.thebarkertheory.org), and has since
broadened to be known as the Developmental Origins of Health and Disease. He first proposed a
link in a 1989 manuscript analyzing areas with high rates of infant mortality (which is strongly
correlated with LBW) and rates of death by ischemic heart disease (Barker et al., 1989). The
study followed over 5,000 English men and found that those at the lowest end of the normal birth
weight scale, as well as those who were small at one year of age, had the greatest heart disease
death rates. Weighing 18 pounds or less at one year of age had doubled the mortality ratio from
ischemic heart disease compared to those who weighed 27 pounds or more at one year of age. In
addition to those findings, another parameter of cardiovascular health, blood pressure, was
measured (Barker et al., 1990). This was also found to correlate with placental mass and birth
weight; the smallest babies with the largest placentas had the highest blood pressure at age 46 to
54, independent of elevated Body Mass Index (BMI) and alcohol consumption. The ratio of fetal
7

size to the mass/area of the placenta was the key measurement in Dr. Barker’s findings. An
enlarged placenta is thought to be an attempt to compensate for poor fetal nutrition.

By

expanding the surface area of the placenta, the availably of whatever nutrients are carried in the
maternal blood supply increases (as reviewed by Robinson et al., (1995)). These early findings
supported Barker’s theory that a healthy intrauterine environment was a greater factor in
preventing adulthood diseases than childhood upbringing (Barker, 1990).

Continued

longitudinal studies have confirmed these findings in Scandinavia cohorts (Finland and Sweden)
(Barker et al., 2002; Lithell et al., 1996).
Research into the fetal origin of disease has broadened into other chronic diseases,
including insulin resistance and diabetes, leading to the phrase, “the thrifty phenotype”. This
phrase emphasizes the need for survival of the fetus under sub-optimal growth conditions (as
reviewed by Hales and Barker, 1992). Hales and Barker (1992) explain that development of
brain neurons, renal glomerui and Beta cells are accelerated compared to other organ systems,
with Beta cell formation at about half of adult capacity at one year of age. If there is a nutritional
deficiency, a thrifty phenotype would allocate available resources to neural and heart
development, resulting in an underdevelopment of the other early developing visceral organs
(kidneys and pancreas) and skin (Thornburg and Morton, 1994). Indeed, amino acid deficiencies
are cited as the largest cause for stymied fetal growth. Not only are amino acids the building
blocks of the tissues themselves, but also the main substrate in energy production early in fetal
life. The main repercussion of this amino acid deficiency is a reduction of Beta cells numbers,
but also causes an abnormal islet structure and vascularization. In an undernourished fetal state,
the need for insulin is low and the consequences of an underdeveloped pancreas in the fetus
would be nil. However, this reduced number and function of the pancreatic cells begets the onset

8

of Type 2 diabetes when over-nutrition in adult life occurs, as the pancreas cannot produce
enough insulin to control blood-glucose levels. In addition to impaired glucose tolerance, an
under-development of renal glomerui in utero leads to renal failure (Hales and Ozanne, 2003).
Studies with Indian children support that reduced fetal weight impaired glucose tolerance and
increased the risk of adult onset of Type 2 diabetes (Yajnik et al., 1995). Although resources are
allocated to the heart and brain differentially than the rest of the developing fetus, heart
conditions can still arise when cardiac structures (specifically the left ventricle and aortic root)
are reduced in size.

Adverse remodeling and growth catch-up later in life can lead to

hypertrophy, which is a risk factor for heart disease (as reviewed by Geelhoed and Joddoe,
(2010)).

In concert with heart disease, vascular structure can also be compromised with

abnormal fetal growth, contributing to endothelial dysfunction and loss of normal elasticity of
the blood vessels, leading to hypertension and atherosclerosis (as reviewed by Geelhoed and
Joddoe (2010)).
Though the emphasis on maternal nutrition is merited, and easy to measure and
manipulate experimentally, a review by Harding (2001) emphasizes that what truly affects fetal
growth is fetal nutrition. Fetal nutrition is dependent on not only maternal nutrient intake, but
maternal metabolism, hormone interplay, blood flow through the uterus and placenta, placenta
metabolism, and nutrient transfer as well. Therefore, compromising the blood flow through the
placenta, as with pregnancy-induced hypertension (PIH) (preeclampsia (PE), toxemia), could be
equally as detrimental to fetal health as low protein intake on the resulting fetal phenotype.
These periods of nutrient deficiency may affect different organ systems by reduced cellular
division, or fluctuations in proper growth factors or hormone production during a specific
system’s critical window of development (Barker, 1995).

9

Cortisol’s Double Edge: Cortisol, Fetal Development and the Role of Placental 11βHydroxysteroid Dehydrogenase Type 2
During critical time points in fetal development, events in utero induce irrevocable
physiological changes to the fetus, also known as fetal programming (Lucas, 1991; Meaney et
al., 2007). While the link between birth weight and adult disease has been supported by Dr.
Barker’s research, further investigation into the mechanism of fetal programming, birth weight,
and disease leads to the complex dynamic of glucocorticoid (mainly cortisol) exposure during
pregnancy (Charmandari et al., 2004).
In adults, cortisol is released in response to a stressor and is the main regulator that
maintains proper blood glucose levels by stimulating gluconeogenesis. Gluconeogenesis is the
conversion of non-carbohydrate substrates (lipids, amino acids) to glucose in the liver. Proper
brain function is dependent on sufficient blood glucose levels because of its inability to use any
other substrate as a fuel source. High concentrations of synthetic glucocorticoids are used to
control inflammation by immune system suppression. Cortisol release is regulated ultimately by
the hypothalamus which releases corticotropin-releasing hormone (CRH). The release of CRH
stimulates the secretion of adrenocorticotropic hormone (ACTH) from the anterior pituitary,
which is what actually acts to release cortisol (Sherwood, 2006)
This stress hormone is also vital to fetal organ maturation, and is involved in additional
pregnancy related events. Cortisol is one potential ligand for the glucocorticoid receptor (GR),
which functions as a ligand-dependent transcription factor.

The α-isoform is expressed

throughout most tissue types and modulates target genes by promoter region binding or
interaction with additional transcription factors (as reviewed by Charmandari et al., (2004)).
Once activated, it functions to remodel chromatin, target initiation sites, and stabilize the RNApolymerase II machinery in order for multiple transcription of target genes (Nicolaides et al.,
10

2010). Describing the role of the receptor in regards to specific gene regulation is beyond the
scope of this review (Oakley and Cidlowski, 2011). Cellular responses to GR activation is tissue
and ligand type dependent. There are also eight receptor variants (A, B, C1, C2, C3, D1, D2 and
D3) that influence gene targets, as well as cofactor surroundings and promoter regions (Karolien,
2010).
Cortisol and the GR play a large role in cellular regulation and fetal development
(described below). However, when a fetus is exposed in utero to an excess of maternally
produced cortisol (via the placenta), a reduction in fetal growth and reduced birth weight can
occur (McTernan et al., 2001). The moderator of this cortisol equilibrium is the enzyme, 11βhydroxysteroid dehydrogenase (11β-HSD) and where considerable focus has been placed in
trying to elucidate the mechanism of low birth weight and fetal programming. 11β-HSD is an
intracellular membrane bound enzyme, found in two isoforms, type 1 and 2 (Lakshmi et al.,
1993). Type 1 (11β-HSD) plays a role in local production of cortisol and is found mainly in the
chorion and amnion (fetal membranes) and fetal tissues. Type 1 converts cortisone, the
biologically inactive ketone, back to the active cortisol via reduction reactions (Sun et al., 1997).
Type 2 performs the reverse reaction, facilitating the unidirectional oxidation of cortisol to
cortisone, with NAD+ as a cofactor (Murphy, 1981).

The 11β-HSD2 enzyme is highly

expressed in at-term placental tissue (37-42 weeks), specifically in the syncytiotrophoblast layer,
where the maternal-fetal interface is located (Pepe et al., 1999; Staud et al., 2006).
Speirs (2004) mapped the GR and 11β-HSD1 expression throughout development in rats.
Increased expression for both was seen in central nervous system, liver, gastrointestinal tract and
lung tissues, indicating that the maturation of these tissues was dependent on the local production
of cortisol.

The increase in expression was organ system dependent and varied across
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developmental time points. The lungs were among the last tissue types to see 11β-HSD1
promotion. For pregnancies at risk for pre-term delivery, cortisol can be used as a therapy by
accelerating the structural development of the lungs, thereby increasing pre-term infant survival
rates (Ballard, 2000). Further evidence of the importance of cortisol in lung maturation was
discovered using GR knock-out mice (Cole et al., 1995).

Neonatal death, due to lung

immaturity, resulted when expression of this critical receptor was repressed.
An additional role of glucocorticoids is labor induction, through prostaglandin
production. When the expression of 11β-HSD1 was increased by the addition of dexamethasone
(a synthetic glucocorticoid) in culture, increased cortisol production in turn stimulated
prostaglandin production in the chorionic trophoblast. Prostaglandins are the main driver of the
positive feedback loop which induces labor (Sun et al., 2002).

Alfaidy et al. (2003) found an

increase of 11β-HSD1 expression in the intrauterine (fetal) membranes during late gestation.
This increase in 11β-HSD1 expression accounts for the increase in cortisol measured in fetal
circulation and amniotic fluid. These findings support the need for additional cortisol production
to induce parturition, with cortisol originating from the placenta, rather than fetal (adrenal) or
maternal origins.
However, an excess of in utero exposure to cortisol has been linked to intrauterine
growth restriction (IUGR) and further health implications later in life such as hypertension
(White, 2001).

The presence of 11β-HSD2 in the syncytiotrophoblast, the tissue of

maternal/infant exchange, suggest that this barrier is designed to protect the fetus from excess
maternal cortisol (Yang, 1997). The 11β-HSD2 enzyme oxidizes (inactivates) 80-90% of the
maternal cortisol, leaving 10-20% to pass into the fetal blood supply without adverse affects on
fetal growth (Waddell et al., 1998). With an increase in cortisol levels later in pregnancy, there is
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concurrent increase in the differentiation of placental cells. Cell differentiation, as a measure of
human chorionic gonadotropin (hCG) secretion, was increased when an 11β-HSD2 inhibitor
(carbenoxolone) was added to cultured trophoblast cells. This decrease in 11β-HSD2 activity
lead to an increase in cortisol concentration (because of reduced cortisol oxidation).

The

increase in cortisol induced the shift from cytotrophoblasts, placental stem cells, into
syncytiotrophoblast cells, the functional cell layer between maternal and fetal blood (Nacharaju
et al., 2004).

Syncytiotrophoblast cells express 11β-HSD2 and with this increased cell

differentiation, the result would be an increase in the placental cortisol barrier, effectively
shielding the fetus and reducing the cortisol levels in utero (Nacharaju et al., 2004)
The inhibition of placental 11β-HSD2 has been shown to alter glucose metabolism in
offspring. Administration of carbenoxolone (inhibitor of 11β-HSD2) to pregnant rats reduced
average fetal weight by 20% (Lindsay et al., 1996). Neonates of the carbenoxolone exposed
pregnancies made up the weight reduction by six months of age, but had significantly higher
fasting plasma glucose and exhibited significantly greater plasma glucose and insulin responses
(10 and 38% higher respectively) to an oral glucose load, increasing the risk of hyperglycemia in
adult life.

A study by Welberg et al. (2005), described similar findings in rats when

carbenoxolone was administered during pregnancy. That study also found that inhibited 11βHSD2 activity was associated with reduced birth and body weight at adulthood. Administration
of a single course of antenatal dexamethasone (a potent synthetic cortisol) reduced 11β-HSD2
expression and fetal weight compared to the placebo group in sheep (Kerzner et al., 2002). Fetal
weight was further reduced with repeated administration of dexamethasone (once a week for five
weeks), though this continued exposure did not significantly change the expression of 11β-HSD2
(anymore than the initial dose did). The positive and adverse consequences of cortisol exposure
13

in pregnancy are well documented. Without it, organ maturation and perturbation progression is
hindered, but an over-exposure has been linked to adverse pregnancy outcomes.
The placental expression of 11β-HSD2 and the oxidation of cortisol becomes more
pronounced as pregnancy progresses (Shams et al., 1998). McTernan et al. (2001) reported a
significant increase (56 fold) in the enzyme’s expression in placentas at term (37-42 weeks) with
normal weight infants compared to first and second trimester measurements. The significant
increase in the enzyme emphasizes its importance in protecting the fetus from excess
glucocorticoid exposure to ensure that the final weeks of growth, which are influential on birth
weight, are uninhibited by the steroid. Unabated fetal exposure, due to mutations in the 11βHSD2 gene are linked to apparent mineralocorticoid excess, a disorder characterized by reduced
birth weight, significant organ damage, and early death (Dave-Sharma et al., 1998). With the
weight of evidence supporting the adverse effects of hypercortisolemia, understanding the
potential influences on the modulation of the expression or the enzyme activity is key to
preventing these adverse effects on infant health.
Maternal Health Influences on 11β-HSD2 Activity and Expression
Studies investigating the relationship between 11β-HSD2 and fetal cortisol exposure
have used three main means of quantifying this enzyme’s presence and efficiency. Enzyme
activity is the measure of how well that enzyme converts its substrate, cortisol, into the product,
cortisone. A decrease in activity could occur through two mechanisms: enzyme inactivation or
substrate competition (Hardy et al., 2001), or due to a decrease in enzyme mRNA transcripts, a
measure of enzyme transcriptional promotion (Sampath-Kumar et al., 1998). A third way of
quantifying this process is to measure the cortisol:cortisone ratio in fetal plasma (Campbell and
Murphy, 1977). Blood is not mixed in the placenta, rather nutrients and wastes are transported to
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and from maternal and fetal blood lines via the syncytiotrophoblast layer of the placenta. This
maternal/fetal interface not only handles nutrient and waste transfer, but also the passage of
maternal cortisol. This interface is where the 11β-HSD2 enzyme is localized, and if properly
functioning and in sufficient supply, 11β-HSD2 converts the majority of the maternal cortisol to
cortisone before encountering the fetal blood supply. Thus, fluctuations in the cortisol:cortisone
ratio in fetal plasma can reflect the efficiency of the enzyme.
A wide range of maternal health conditions have been shown to play a significant part in
the activity/expression of 11β-HSD2. One that parallels Barker’s findings is maternal nutrition.
McMullen et al. (2004) tested 11β-HSD2 activity and the ratio of cortisol:cortisone in fetal
plasma in pregnant ewes fed a 70% maintenance diet. While maintaining the ewes and fetuses,
this diet was nutritionally deficient.

Sustained from gestational day 26 onward, this diet

decreased 11β-HSD2 enzyme activity by 52% on day 90 of gestation; fetal growth was also
restricted as a result. This pattern of nutritional restriction, however, did not alter the fetal
cortisol:cortisone plasma ratio. Lesage et al. (2001) placed rats on a 50% nutritional restriction
during the last week of gestation. Maternal corticosterone (the murine cortisol equivalent) levels
increased, along with maternal adrenal weight, while placental 11β-HSD2 expression decreased.
This rise in maternal cortisol levels, coupled with a decrease in 11β-HSD2 expression, resulted
in excess fetal cortisol exposure, and a decrease in fetal weight resulted. To deduce whether the
increased cortisol exposure via increased maternal production, or the nutritional deficiencies was
the cause of the 11β-HSD2 expression decrease and reduced fetal growth, a second group of
mothers were placed on the same nutritional restriction pattern. In the second group however, a
basal level of cortisol was maintained by artificial means following the removal of their adrenal
gland.

This was done to test the effects of the diet restriction and null maternal cortisol
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production. The same reduction of 11β-HSD2 expression and fetal weight resulted, mirroring
the adrenal intact mothers, which showed that the nutritional state of the doe, and not maternal
cortisol levels, decreased 11β-HSD2 expression and lead to the reduced fetal weight. LangleyEvans et al. (1996) also showed a similar reduction of 11β-HSD2 enzyme activity in rats when
mothers were placed on a mildly restricted protein diet. Pups of the protein-restricted mothers
had an increased adult systolic blood pressure compared to controls.

Additional placental

enzymes were tested for activity (MDase activity, PKase activity), as well as total placental
protein. These measurements were not significantly different from controls, indicating that
overall placental function was maintained; with the protein deficiency specifically affecting the
11β-HSD2 enzyme.
Chronic maternal stress is another important maternal factor for maintaining the proper
11β-HSD2 placental cortisol barrier. At gestational day 20, a 160% increase in 11β-HSD2
activity was reported by Welberg et al., (2005) with the administration of acute maternal stress
(via a restraint test) in rats. However, this ability to up-regulate the enzyme was inhibited by
90% with sustained chronic maternal stress on days 14-19. So although acute stress can induce
enzyme activity, when stress is sustained, that ability is diminished. The effects of other stress
hormones, catecholamines (norepinephrine, and epinephrine) and proinflammatory cytokines
(interleukin (IL)-1, IL-6, and tumor necrosis factor-α) have all been shown to down regulate
expression and activity of 11β-HSD2 in placenta tissue cultures (Kossintseva et al., 2006; Sarkar
et al., 2001). This 11β-HSD2 reduction is also seen in reduced oxygen environments, such as
pregnancies complicated with preeclampsia (PE). Hardy and Yang (2002) demonstrated that
cytotrophoblast cells, when cultured under hypoxic conditions, do not differentiate into
syncytiotrophoblast cells, the cells that predominantly express 11β-HSD2, which could lead to a
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reduction of the enzyme. Placentas from normal and PE pregnancies were compared by Alfaidy
et al., (2002); 11β-HSD2 expression was reduced with PE pregnancies when compared to
gestationally matched controls. In the same study, villous explants from first trimester (5–8
week gestation) and at-term placentas were cultured under 20% O2 or 3% O2 atmospheres. At
both time points, the increased O2 atmosphere contributed to an increased in 11β-HSD2
expression. In the at-term placentas, an 140% increase in activity was observed.
Although not a maternal illness, intrauterine growth restriction (IUGR), babies born
small even at full term (Adam, 2008; Wilcox, 2001), has been associated with a decrease in
placental 11β-HSD2 activity and expression (Dy et al., 2008; McTernan et al., 2001; Shams et
al., 1998). However, there is refuting research about this association (Rogerson et al., 1997).
With the importance of 11β-HSD2 in the prevention of excessive cortisol exposure to the
fetus, and the possibility of its inhibition (activity and expression) further merits investigation as
to what other compounds impact this important placental barrier.
Environmental Influences of 11β-HSD2 Activity and Expression
With the increasing understanding of the important physiological role of cortisol,
research into potential environmental contaminates that disrupt the 11β-HSD2 axis need to be
examined (Odermatt and Gumy, 2008; Odermatt et al., 2006). Metals have been shown to alter
the activity and expression of this enzyme. Yang et al. (2006) reported that cadmium, a metal
classified as a human carcinogen by the World Health Organization’s (WHO) International
Agency for Research on Cancer (World Health Organization, 1993) also is an inhibitor to 11βHSD2 activity in cultured trophoblast cells. A 24-hour exposure to 1 µM CdCl2 reduced the
cortisol conversion activity of 11β-HSD2 by 80%. Along with enzyme activity, 11β-HSD2 gene
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transcription was decreased with cadmium exposure, suggesting that the decrease in activity was
due to a reduction of gene transcription. Ronco et al. (2009) reported a decrease in the birth
weight (8.4%) in rats with a placental concentration of 50 ppm of Cd+2, which was linked to an
increase in corticosterone, the glucocorticoid equivalent in rats. There was no reduction in 11βHSD2 activity, however. Hardy et al. (2001) demonstrated, after culturing placenta tissue in
vitro, that similar to cadmium, calcium, another divalent element, inhibited 11β-HSD2 activity
through an alteration in the catalytic efficiency by a disruption of the enzyme itself. Activity
inhibition of up to 50% was observed at calcium concentrations from 22 to 268 nM, but the
activity inhibition was reversible with the addition of a chelator. Zinc (also divalent) was
identified by Niu and Yang (2002) as a 11β-HSD2 activity inhibitor, with an IC50 of 2.5 µM.
The inactivation of metals, through the use of a metal chelator (e.g., EDTA, EGTA or TPEN) has
been shown to significantly increase 11β-HSD2 activity in the placental microsomal fraction or
tissue culture (Niu and Yang, 2002; Yang et al., 2002). It is clear through both the decrease in
activity and expression of 11β-HSD2 by metals, and by the increase in activity with the chelation
of metals, that 11β-HSD2 is sensitive to these trace elements. Organotins (Di- and tributyltin
(DBT, TBT) as well as di- and triphenyltin (DPT, TPT)) were tested for 11β-HSD2 inhibition
(Atanasov et al., 2005). The IC50 in intact cells ranged from 0.99 (± 0.24) to 2.89 (± 0.59) µM
with TPT and DPT, respectfully.
In addition to metals, other organic pollutants, phthalates (dipropyl phthalate (DPrP)
and di-n-butyl phthalate (DBP), were shown to disrupt 11β-HSD2 activity when tested on rat
kidney tissue (IC50 of 85.59 μM and 13.69 μM, respectfully) (Zhao et al., 2010). The extent of
activity inhibition was structurally dependent, specifically on the number and arrangement of
carbons in the alcohol moiety. One, two, and 5-10 carbons were ineffective in enzyme
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disruption, except when cyclized (6-carbons).

Another class of organic compounds,

dithiocarbamate (DTC), showed similar inhibition (Atanasov et al., 2003). Six DTC congers
were tested (Thiram, Disulfiram, DEDTC, PDTC, Maneb Zineb) and resulted in a range of IC50
from Disulfiram at 128 (±21) nM to Zineb 31 (±18) µM.

Additional screening has been

performed to find other possible 11β-HDS inhibitors (Schweizer et al., 2003). It is interesting to
see the inhibition of type 2, and not type 1 in with organotins and dithiocarbamates, both through
the proposed disruption at the Cys90 (Atanasov et al., 2005; Atanasov et al., 2003), suggesting
sensitivity to outside xenobiotics and compounding factors for the disruption of proper placental
cortisol barrier function.

Birth Weight as an Individual Measurement and the GROW Curve
A 2000 study done by Savitz et al. (2000) analyzed births in New York City, NY, US
and found that while the majority of low birth weight infants were premature (69.2%), just more
than half (50.2%) premature infants were low birth weight. So while gestational period is a
confounder for overall birth weight, there are other mechanisms that induce low birth weight
other than length of development.
A simple assessment based on fetal weight alone ignores other important variables that
influence birth weight, including maternal height and weight, parity, ethnicity and infant sex
(Gardosi et al., 1992). With the incorporation of these factors, infants can then be grouped as
small for gestational age (< 10th centile), average, or large for gestational age (>90th centile) (i.e.,
SGA, AGA, LGA). With these physiological characteristics incorporated into an adjusted
growth curve, a more accurate assessment of whether or not the infant’s weight was influenced
by pathological factors is gained. After assessing 4,179 births in the United Kingdom, Gardosi
and Chang (1992) found that 28% of SGA babies were within the normal range when the
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adjusted charts were used, emphasizing the importance of incorporating more than just
gestational age into proper birth weight.
Software developed by Gardosi and Francis (2009) can be used to calculate an
individual growth centile, using the physiological parameters (i.e., maternal height, maternal
weight at first clinical visit, parity and ethnic group), which are customized to different
geographical regions.

These parameters generate a Term Optimal Weight, which is then

extended proportionally to give a Gestation Related Optimal Weight (GROW) curve. Finally,
the actual birth weight of the infant and the gestational age at delivery is factored in to produce
the birth weight centile (BWC) ranking.

Expression Quantification and New Standards for qRT-PCR
Northern blots can be used as to compare mRNA production between experimental
treatments. RNA is first separated by size via gel electrophoresis, transferred to a membrane and
labeled probes are then used to target genes of interest (Glick and Pasternak, 2003). However, a
more sensitive technique for quantification of gene expression is quantitative (real time) reverse
transcription polymerase chain reaction (qRT-PCR). Total RNA is first isolated from the sample
of interest at a specific time point or under a certain condition, and is then reverse transcribed to
complementary DNA (cDNA). This cDNA sample is then placed into a thermocycler with
target-gene specific primers, and a fluorescent dye that only fluoresces when bound to double
stranded (ds) DNA, referred to as an intercalation dyes. As the thermocyler completes a cycle
(denature, anneal, polymerize, repeat), the cDNA sample (PCR product), which originated from
the RNA transcripts, is amplified, increasing the fluorescence proportionally. A threshold level
for the fluorescence is set automatically by the cycler. When the fluorescence of a sample
surpasses the threshold, the cycle number (Ct) is recorded. Fewer cycles are required to generate
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fluorescence sufficient to surpass the threshold when increased gene-of-interest transcripts are
present in the initial sample. In Figure 1, Position A represents the sample with the most RNA
transcripts of interest (also known as copy number). Position B is the sample with the lowest
copy number. The green horizontal line is the fluorescence threshold where the Ct value for each
sample will be taken.
The specificity of the amplification process is assessed through a melt curve (Figure 2).
After the polymerization step for qRT-PCR, the temperature is incrementally increased, with
corresponding fluorescence detection. Increased temperature denatures the dsDNA strands (PCR
product), decreasing the fluorescence produced by the intercalation dye, which only fluoresces in
the presence of dsDNA. A desired melt curve has only one peak, indicating no primer dimer
interaction and no additional amplification of contaminating DNA.

Figure 1
qRT-PCR reaction plot of fluorescence of intercalation dye and cycle number. Sample A has the
most RNA transcripts of interest (copy number). B is the sample with the lowest copy number.
The green line is the fluorescence threshold where the Ct value for each sample will be taken.
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Figure 2
Melt curve plot of a single gene using qRT-PCR. Increasing the temperature incrementally
denatures the dsDNA strands (PCR product), decreasing the fluorescence produced by the
intercalation dye. One peak indicates no primer dimer interactions or DNA contamination.

With the use of qRT-PCR increasing over the past decade, more stringent and consistent
requirements for the publication of qRT-PCR are needed (Bustin et al., 2009). One important
area is in the selection and number of reference genes (Bustin et al., 2005). Reference genes are
used as an internal standard to normalize the gene of interest, which controls for variations in
several steps: RNA extraction, reverse-transcription and amplification. These controls allow for
the comparisons of RNA concentrations across different samples (Bustin et al., 2009).
Reference genes are selected based on their consistent expression over developmental time
points and cellular modulations.

An abundance of reference gene possibilities have been

archived in the RTPrimer Data Base, with the goal of uniformity and standardization in primer
design (Pattyn et al., 2003). Currently, the database holds 8,310 primer sets for twenty-four
organisms, bacteria and viruses. For this study, three genes were evaluated as possible reference
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genes, ribosomal 18S RNA, beta actin (ACTB) and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH).
With the mounting evidence that over-exposure to cortisol in utero influences birth
weight, the current study examined the correlation between birth weight and a calculated birth
weight centile with placental expression of 11β-HSD2. Additionally, other maternal factors that
affect birth weight, the birth weight centile and 11β-HSD2 expression were examined.
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CHAPTER 3
MATERIALS AND METHODS

Subjects
This study received approval from and annual renewal by two IRBs in the University of
Tennessee system: Chattanooga Unit of the College of Medicine Institutional Review Board and
University of Tennessee Graduate School of Medicine Institutional Review Board. Collection
was done at Erlanger Hospital, Chattanooga, TN and was sustained between June of 2007 to July
of 2010. Sample selection was based on personal arrival time and time of placental delivery.
From placentas collected one hour after the delivery (n=242), and which would have otherwise
been discarded, a thin, five gram sample was removed from an area adjacent to the umbilical
cord, preserved with 25 ml of RNAlater (an RNA Stabilization reagent, Qiagen, Valencia, CA)
and stored at -20°C. Additional maternal and infant data were collected from medical records.
Placentas were collected from singleton births from HIV and hepatitis negative mothers over 18
years of age. Consent was obtained when possible.
Assessment of 11β-HSD2 Expression: qRT-PCR
To determine whether the expression of 11β-HSD2 correlated with birth weight, the
relative abundance of 11β-HSD2 mRNA in preserved placenta samples was assessed by a twostep qRT-PCR, as described previously (Sharma et al., 2009). Briefly, total RNA was extracted
from an approximately 30 mg RNALater preserved sample using an RNase Mini Kit Plus
(Qiagen Hercules, CA) according to manufacturer’s instructions.
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Briefly, tissues were

mechanically homogenized in lysis buffer containing 1% β-mercaptoethanol. Genomic DNA
removal from homogenized lysate was carried out by supplied gDNA Eliminator spin columns.
Aliquots were stored at - 80° until time of use. Agarose gel electrophoresis was used to evaluate
RNA quality through detection of 18S and 28S rRNA bands on a 1% RNase-free agarose gel, as
well as assessment of RNA purity, ensuring the absence of DNA contamination. RNA was
quantified by spectrophotometry (NanoDrop 2000c, Thermo Fisher Scientific) measuring the
A260/A280. One microgram of total RNA was reverse transcribed in a total volume of 20 ul
using iScript cDNA Synthesis Kit (BioRad, Hercules, CA) according to the manufacturer’s
instructions. Reactions were carried out in supplied reaction buffer according to the following
incubation parameters: 5 min equilibration at 25°C, 30 min reverse transcription at 42°C, 5 min
enzyme inactivation at 85°C. The diluted RNA was retroactively assayed to confirm absence of
genomic DNA contamination. Gene transcript levels of ribosomal 18S, ACTB, GAPDH and
11β-HSD2, using primers listed in Table 1, were quantified in triplicate with the Ssofast Eva
Green assay using the Ssofast Eva Green master mix (Biorad) under universal thermal cycling
parameters (2 min at 50 C and 10 min at 95 C, followed by 40 cycles of 15 sec at 95 C and 1 min
at 60 C) on the Biorad iQ5 Real-Time PCR Detection System. The specificity of the Ssofast Eva
Green assays was verified by performing a melting curve analyses, confirming only
amplification of the primer/gene product with the generation of a single peak (Figure 2). Levels
of 18S, ACTB, GAPDH and 11β-HSD2 mRNA in each RNA sample were quantified using the
relative standard curve method, which involves the generation of a standard curve from serial
dilutions of untreated control cDNA, ranging from 2 x 101 to 2 x 108 copies. For each RNA
sample, the relative amounts of ACTB, GAPDH and 11β-HSD2 were determined and the ratio of
11β-HSD2 to both ACTB and GAPDH was calculated using the ∆∆CT method (Livak and
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Schmittgen, 2001), resulting in the final normalized 11β-HSD2 expression level (Sharma et al.,
2009) (see Determination of Reference Gene Expression Stability below). An identical cDNA
sample was used as an inter-run control across all plates of the same gene to assess the
consistency between qRT-PCR runs of the same gene (Hellemans et al., 2007). Plate efficiencies
for each gene exceeded 92.5% (14 plates/gene).

Table 1
Sequences for 11β-HSD2 and all potential reference genes primers, forward (FP) and reverse (RP).
Gene Name

Primer sequence (5’-3’)

18S-FP
18S-RP
ACTB- FP
ACTB- RP
GAPDH-FP
GAPDH- RP
11β-HSD2 -FP
11β-HSD2 - RP

GTAACCCGTTGAACCCCATT
CCATCCAATCGGTAGTAGCG
GGCCGCGGTGTACGCCAACACAGTGCTG
CCCGGGGCCGTCATACTCCTGCTTGCTG
CCTGTTCGACAGTCAGCCG
CGACCAAATCCGTTGACTCC
TCAAGACAGAGTCAGTGAGAAACG
GGAACTGCCCATGCAAGTG

Product size
Reference
(base pairs)
153
(Zhang et al., 2011)
228

(Murphy, 2002)

101

(Sturla et al., 2009)

129

(Murphy, 2002)

Determination of Reference Gene Expression Stability
From the three possible reference genes (18S, ACTB and GAPDH), sixty samples were
analyzed for consistency of expression using geNorm (Vandesompele et al., 2002). The geNorm
software ranks potential reference genes according to variances in their expression profile.
Those with the lowest gene expression stability measure (M) are selected as the best possible
reference genes. NormFinder (Andersen et al., 2004) was also used to calculate the stability of
the reference gene expression. The initial analysis resulted in 18S receiving the greatest M value
of all three potential genes, and was subsequently eliminated. The final M value for ACTB and
GAPDH was 0.879, indicating an inherently stable expression.
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Birth weight centile calculation
GROW software was obtained for the United States coefficients (Gardosi and Francis,
2009). Data for the gestational age adjustment (parity, maternal height/weight, ethnicity, infant
sex and weight) was obtained from medical charts. Gestational age was based on best obstetric
estimate. This incorporated the use of first trimester ultrasound that was within +/- 3 days of last
missed period (LMP) or a second trimester (< 20 weeks gestation) that was +/- 7 days of LMP.

Statistical Analysis
Study parameters included normalized 11β-HSD2 expression, birth weight centiles and
unadjusted birth weight. These three endpoints were analyzed based on maternal age, marital
status, pre-pregnancy BMI, maternal smoking and drug use, race and education. Additional
comparisons were done between infant sex, and complicated vs. non-complicated pregnancies.
Data were complete for the three study parameters (birth weight centiles, 11β-HSD2 expression,
and birth weight) for a total of 242 samples. Of those 242, 51 were classified as complicated,
which included IUGR (n=5), oligohydramnios (n=5), PIH/PE (n =9), Non-reassuring fetal heart
rate (NRFHR) (n=15), and pre-term labor (PTL) (n=13). One hundred and ninety one were
considered uncomplicated. Self-reported smoking, drug use (n =5) and alcohol consumption (n
=2) were lumped together (n = 44) and compared against uncomplicated pregnancies with no
drug/tobacco use (n = 147). Education and marital status data were missing from some births (n
= 199 and 234 respectfully). The top three races (Hispanic, Caucasian, African American) were
used for comparison of 11β-HSD2 expression, birth weight centile and unadjusted birth weight
(n = 240). Calculation of maternal Body Mass Index (BMI) was based on weight at first booking
and maternal height followed the standard calculation from Keys (Keys et al., 1972). Individual
BMI was calculated for all subjects (n = 242) and delineated according to standard guidelines,
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released by the World Health Organization (2011). A BMI score of less than 18.5 is considered
underweight, 18.5-24.9 is considered normal, 25-29.9 is classified as overweight, and a BMI
score of greater than 30 is considered obese.
Comparisons based on maternal age (less than 35 vs. 35 and up), marital status (single
vs. married), pre-pregnancy BMI (under vs. average vs. overweight vs. obese), maternal drug use
in non-complicated pregnancies (use vs. non-use), race (Caucasian vs. African American vs.
Hispanic) and maternal education (less than high school vs. high school/GED vs. some college),
infant sex and pregnancy type (complicated vs. non-complicated; complications are listed above)
were done with either a Mann-Whitney Rank Sum Test or a Kruskal-Wallis One Way Analysis
of Variance on Ranks, with accompanying Dunn post hoc test. Correlations between normalized
11β-HSD2 expression, birth weight centiles, gestational age, and unadjusted birth weight were
analyzed with a Kruskal-Wallis One Way Analysis of Variance on Ranks. Statistical analysis
was done with SigmaPlot 12.0.

28

CHAPTER 4
RESULTS
Analysis of Study Parameters: Birth Weight Centiles, 11β-HSD2 Expression, and Birth Weight
All data were subjected to a Shapiro-Wilk Normality Test and were non-normal (p
<0.001). Log and inverse transformations were attempted, but did not improve data distribution.
Non-parametric tests, or tests of ranks, (Kruskal-Wallis One Way Analysis of Variance on
Ranks, Mann-Whitney Rank Sum Test, Spearman Rank Order Correlation) were continued
throughout the analysis, and medians reported (Table 2).

Table 2
Distribution of study parameters reported as 25th, 50th and 75th quartiles as well as mean and
standard deviation (Std Dev).
Study Parameter a
Birth weight centile (%)b
11β-HSD2 Expressionc
Birth weight (g)

25% quartile
18.3
0.159
2776.0

Median
75% quartile
44.0
72.1
0.291
0.488
3184.0
3539.5

Mean
46.1
0.365
3121.6

Std Dev
31.5
0.279
664.4

a

For all parameters, n = 242.

b

Birth weight centile was calculated using GROW Software (Gardosi and Francis, 2009).

c

Expression of 11β-HSD2 was normalized using the ∆∆CT method with reference genes,
ACTB and GAPDH.

Birth weight ranged from 968 g to 4733 g and the birth weight distribution was
negatively skewed (Figure 3). Fourteen percent of the sample population was LBW. According
to the birth weight centile calculation, 17% were of births were SGA, 70% were AGA and 13%
were

LGA.
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Figure 3
Distribution of birth weights, n = 242.

Birth weight centile, 11β-HSD2 expression, and birth weight were analyzed based on
maternal age, marital status, pre-pregnancy BMI, maternal smoking and drug use, race and
maternal education. Additional comparisons were done between infant sex and complicated vs.
non-complicated pregnancies. Birth weight was significantly different between married and
single women (p <0.001) (Figure 4), Caucasian and African American mothers (p = 0.023)
(Figure 5), and obese and underweight women (p = 0.029) (Figure 6) and complicated vs. noncomplicated pregnancies (p = <0.001). Significant differences in infant birth weight centile were
found between married and single women (p = 0.011) and complicated vs. non-complicated
pregnancies (p = 0.027). Between those eight categories, there was no difference in 11β-HSD2
expression (Table 3). Thus, race, education, age, smoking, marital status, maternal BMI, nor
pregnancy complications were associated with changes in 11β-HSD2 expression. Additionally,
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there was no significant difference in Type 2 expression between low birth weight (<2,500 g)
and normal birth weight infants, or when comparing SGA, AGA and LGA infants.
There was a significant, positive correlation between birth weight and maternal BMI (n
= 242, p=0.0471) and gestational age (p < 0.001) using a Spearman Rank Order Correlation, as
well as with 11β-HSD2 expression and birth weight centile in the uncomplicated pregnancies (n
= 191, p=0.024.
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Figure 4
Effects of Marital Status on Average Birth Weight (Single Mothers vs. Married Mothers).
Significant differences (p < 0.05) are denoted with an asterisk (*). Error bars signify standard
error. n = 126 for single mothers, 108 for married mothers. Average (± standard deviation) birth
weight for single mothers was 2977.1 g (±618.1) and 3268.6 g (±685.3) for married mothers.
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Figure 5
Effects of Race on Average Birth Weight (Caucasian vs. African American vs. Hispanic).
Significant differences (p < 0.05) are denoted with an asterisk (*). Error bars signify standard
error. n = 155 for Caucasian mothers, 46 for African American mothers and 39 for Hispanic
mothers. Average (± standard deviation) birth weight for Caucasian mothers was 3196.7 g
(±624.5), 2944.2 g (±551.4) for African American mothers and 3024.7 g (±885.6) for Hispanic
mothers.
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Figure 6
Effects of Pre-Pregnancy BMI on Average Birth Weight (under vs. average vs. overweight vs.
obese). Significant differences (p < 0.05) are denoted with an asterisk (*). Error bars signify
standard error. n = 9 for underweight mothers, 96 for average weight mothers, 70 for overweight
mothers and 67 for obese mothers. Average (± standard deviation) birth weight for underweight
mothers was 2594.3 g (±670.2), 3090.8 g (±663.7) for normal weight mothers, 3112.8 g (±701.6)
for overweight mothers and 3251.5 g (±607.8) for obese mothers.
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Table 3
Relationship of maternal and infant parameters relative to birth weight centile, normalized 11βHSD2 expression, and unadjusted birth weight. Total number (n) in each category are reported
along with median values. p-values comparing study parameters within maternal/infant
characteristics are in gray.
Statistical Grouping
Maternal Age
<35
≥35
Marital Status
Single
Married
Pre-preg. (BMI)c
Underweight (<18.5)
Average (18.5-24.9)
Overweight (25-29.9)
Obese (>30)
Drug used
No drugs consumed
Drugs used
Race
Caucasian
African American
Hispanic
Education
< high school
HS/GED
any college
Pregnancy type
Non-complicated
Complicated
Infant Sex
Female
Male

Birth Weight
Centile
0.352
41.53
60.53
0.011*
38.19
50.41
0.128
18.55
51.69
37.02
47.50
0.618
50.38
46.53
0.167
44.56
36.23
53.82
0.307
49.88
51.91
36.76
0.027*
45.525
27.671
0.863
39.17
44.25

Normalized 11β-HSD2
Expressiona
0.617
0.297
0.254
0.595
0.301
0.289
0.480
0.446
0.275
0.298
0.284
0.732
0.266
0.248
0.771
0.303
0.293
0.266
0.639
0.253
0.284
0.306
0.507
0.282
0.332
0.753
0.304
0.286

Birth Weight (g)

n

% of Sample
Population

225
17

93
7

126
108

54
46

9
96
70
67

4
39
29
28

147
44

77
23

155
46
39

64
19
17

67
56
76

34
28
38

191
51

79
21

132
110

54
46

0.933
3195
3155
<0.001*
2972
3269
0.029*
2578 (A)b
3155 (AB)
3228 (AB)
3354 (B)
0.090
3333
3282
0.023*
3248 (A)b
2984 (B)
3127(AB)
0.114
3126
3334
3073
<0.001*
2565
3301
0.886
3163
3207

a

11β-HSD2 was normalized using the ∆∆CT method with ACTB and GAPDH.

b

Significant differences were accompanied by a Dunn’s post hoc test. Statistically similar
median values are indicated by using identical letters (e.g., A is significantly different than
B).

c

Body Mass Index

d

In un-complicated pregnancies

*

Significant differences among groups (p-value < 0.05)
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CHAPTER 5
DISCUSSION

The present study was designed to investigate the expression of 11β-HSD type 2 and its
possible correlation with raw birth weight and (or) a maternal physiology/gestational age
adjusted birth weight centile. To our knowledge, no research has used such a large sampling to
assess the relationships between the expression of this enzyme using qRT-PCR over a range of
birth weights of non-complicated pregnancies and various maternal parameters and fetal
parameters. The 11β-HSD2 expression data, in addition to birth weight and the adjusted birth
weight centile, were examined in a broader scale with such maternal factors as age, BMI,
marriage status, education, race and smoking.

Significant Findings: Race, Maternal BMI and Marital Status Are Correlated With Birth Weight
One significant finding that is well supported in the literature is the disparity between
white and black infant birth weight. The present study shows a significantly lower birth weight
between Caucasian and African American women, which is mirrored by the state as a whole (TN
Department of Health). In addition, data from the State shows that black Tennessee infants are
still at greater risk for infant mortality than white infants across all maternal ages, among
mothers who hold a college degree, and mothers without maternal care (Corniola et al., 2006).
The pattern of reduced birth weight infants born to American born black mothers is a
nationwide trend. A study by David and Collins (1997) sought to determine whether this trend
was due to a genetic predisposition to smallness by compiling data from infants born to African-
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born women in the United States. The researchers looked at mothers who immigrated from West
Africa, where it is thought that American born blacks can trace back ancestry due to the slave
trade of the 17th and 18th century. Three quarters of American black genetic heritage originates
from this area; the last quarter coming from European descent, so if there was a genetic
predisposition to reduced birth weight, these two black populations should share that. However,
birth weight distribution between U.S.-born white women and African-born black women were
the same, and both populations gave rise to larger infants than infants born to U.S. born black
women. The same parallel was seen in very low birth weight births. Without a genetic link to
smaller infant size, continued investigation into community and psychological factors are
merited (Geronimus, 1992).
The current study showed a significant difference in birth weight between under weight
and obese mothers, as well as between married versus single mothers. Ehrenberg et al. (2003)
reported that mothers that were underweight prior to conception had an increased risk of preterm
labor, intrauterine growth restriction and low birth weight. Increased maternal BMI has been
shown to increase birth weight due to an increase in placental nutrient transport (Jansson et al.,
2008) and incidences of macrosomia (excessive birth weight) increase with maternal BMI
(Frederick et al., 2008; Hull et al., 2008). Previous research shows that LBW, pre-term labor and
small for gestational age births were seen more often with single versus married women (Shah et
al., 2011). A large scale study done by the Centers for Disease Control in the U.S. found an
increased risk of stillbirth, total infant deaths, and Sudden Infant Death Syndrome (SIDS) among
single woman (Balayla et al., 2011). The significant differences in birth weight reported in the
current study between difference races, marital status and maternal BMI are all supported in the
literature. An accompanying decrease in 11β-HSD2 expression was not reported in this study,
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thus the difference between these categories was not due to an insufficient placental cortisol
barrier.
There was no difference in birth weight, birth weight centile or 11β-HSD2 expression in
mothers over the age of 35. Maternal age of 35 or more years is considered high risk and
correlated with adverse pregnancy outcomes compared to mothers between the ages of 20-24
(Joseph et al., 2005). Mothers between 35-39 years of age had an increased risk of maternal
complications (hypertension, diabetes mellitus, placental abruption, or placenta previa) as well as
pre-term and SGA births. Although these effects are seen with increasing age, these data support
that aging mothers in the present study are able to maintain normal 11β-HSD2 expression, and
birth weight, as well as mothers under the age of 35.
An additional variable that has been shown to influence fetal growth is the use of
tobacco, drugs or alcohol during pregnancy (Lieberman et al., 1994; Wright et al., 1983;
Zuckerman et al., 1989). The current study lumped any use of drugs (tobacco, alcohol or
marijuana) together, though tobacco use was most commonly consumed (85%). The use of these
substances during pregnancy was compared among uncomplicated pregnancies.

It is well

documented that smoking has a significant negative effect on birth weight. A study by Krentz et
al., (2011) showed that birth weight was affected in a dose-dependent manner, ranging from 0-20
cigarettes smoked per day. Chen et al., (2007) tested the effects of nicotine on fetal growth
through subcutaneous administration of nicotine in rats.

Placenta 11β-HSD2 expression

decreased at mid to late gestation, resulting in IUGR neonates. Despite these studies, there was
no significant difference in birth weight or 11β-HSD2 expression between mothers whom used
drugs, alcohol or tobacco and those that did not.
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11β-HSD2 expression was compared among LBW infants and normal weight infants.
Additionally, 11β-HSD2 expression was compared among SGA infants, as well as AGA and
LGA infants. Several studies have shown a concurrent decrease in expression and birth weight
(McTernan et al., 2001; Murphy et al., 2002), but this study did not. Rogerson et al. (1997)
quantified 11β-HSD2 expression through a Northern blot analysis and compared expression with
raw birth weight, as well as placental weight, in 110 placentas across various gestational ages,
races, and maternal ages. Rogerson et al. found no difference in expression between maternal
age, gestational age or race, which mirror results from the present study.

However, no

correlation was found between expression and infant birth weight. Although a similar design,
the current study uses a more precise technique, a larger sample size, and adjusts for
confounding birth weight variables not done by Rogerson et al., thus, a different study outcome.

Importance of Birth Weight Adjustment
Many factors contribute to an infant’s final birth weight. Although it has been used to
make predictions of adult adverse health effects of smaller infants (as with Dr. Barker’s studies
discussed above), the use of raw birth weight alone may not be a sensitive enough endpoint for
subtle correlations with variables such as environmental contaminates, and as the data showed in
this study, 11β-HSD2 expression. Therefore, confounding variables that have been shown to
significantly influence birth weight need to be controlled for in order to see these extraneous
variables. This is a well-established practice. For example, Fei et al., (2007) found a negative
correlation with perfluorinated compounds and birth weight after adjusting for maternal age,
parity, socio-occupational status, pre-pregnancy BMI, smoking during pregnancy, infant sex, and
gestational age, with the most substantial confounding variables being parity and pre-pregnancy
BMI. Fei’s study also excluded births from the Danish cohort with congenital malformations,
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supporting the need for some selection before a final correlation between the BWC and enzyme
expression was found. Similar elimination of pregnancy complications was done by Washino et
al., (2009) and a significant inverse correlation between the perfluorinated compounds and birth
weight was found only after the above parameters were adjusted for (in addition to alcohol,
caffeine consumption, annual house hold income and education level). The lumping of nonreassuring fetal heart rate (NRFHR) in with complicated pregnancies, and being subsequently
discarded from the final expression/BWC correlation could be disputed. Clinically, NRFHR is
assigned for a variety of conditions, which may or may not indicate, in and by itself, abnormal
fetal conditions or affect birth weight (Adair, 2011). However, because of its high incidence in
the sample population, it was lumped into pregnancy complications.
Although the present study lacked the resources to incorporate some of the variables
mentioned above, the GROW software adjusted for parity, pre-pregnancy BMI, infant sex, and
gestational age. Only after these variables were accounted for was there a correlation with 11βHSD2 expression. More extensive analysis to control for these confounding factors not used in
GROW would presumably produce a more accurate account of fetal growth.

Additional

maternal parameters that have been shown to affect fetal health, and 11β-HSD2 expression or
activity (e.g., maternal nutrition, stress) should be incorporated into to future studies.

Data Gaps and Uncertainties
The present study examined the expression of 11β-HSD2 in placental tissue over a
variety of infant and maternal parameters.

However, this measurement of fetal health is

incomplete without accompanying 11β-HSD2 activity data. Enzyme activity is affected by both
reduced expression (enzyme production), but also by the physical disruption of the enzyme. If
environmental contaminants are indeed a factor in increased in utero cortisol exposure, and beget
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restricted fetal growth in Hamilton County, a physical disruption of the enzyme seems a more
plausible mechanism over reduced expression.

In addition to activity, the ratio of

cortisol:cortisone in fetal plasma is a measure of actual cortisol exposure. With these two
additional measurements, a more complete picture of cortisol, the placental 11β-HSD2 barrier
and fetal growth could be constructed.
The current study made no attempt to evaluate any additional parameters that are
important in maintaining an healthy pregnancy.

Numerous studies have emphasized the

importance of maternal and/or cord blood levels of adipocytokines (leptin, adiponectin, ect.) and
Insulin-Like Growth Factors (Briana and Malamitsi-Puchner, 2009; Christou et al., 2001;
Kyriakakou et al., 2008; Street et al., 2006; Tsai et al., 2004) on proper fetal growth. Proper fetal
nutrition, in particular amino acid transport via the placenta, is another potential focus for
research pertaining to proper fetal health and birth weight (Bajoria et al., 2002; Keating et al.,
2009; Roos et al., 2004; Sibley, 2009). Begetting sufficient fetal nutrition is proper placental
function, especially in the area of uterine perfusion and its effect on fetal weight and subsequent
adult cardiovascular health (Alexander, 2003). Langley-Evans’ study (1996) quantified three
other placental enzymes, as well as protein to ensure that placental function was not a
confounding variable on the growth of the fetus.
The birth weight centile calculation did take into consideration gestation age, which is
strongly correlated with birth weight. However, studies have shown that clinical estimates of
gestational age can be inaccurate. Dietz et al. (2007) reported that African American and
Hispanic women, younger and less-educated women, and those who entered prenatal care after
the second month of pregnancy have the most inconsistent gestational age estimates. The ‘gold
standard’ of the gestational age estimate is based off of ultrasounds before the 20th week of
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pregnancy, but even then there have been reported inaccuracies (Henriksen et al., 1995).
However, gestational age estimates based on ultrasound data have been shown to be much more
accurate than recalling the mothers last missed period (Gjessing et al., 1999; Kramer et al.,
1988). Adjustments to birth weight are dependent on high quality gestational age data, however,
even the best measurements of gestational age can be a source of uncertainly.
Finally, the definition of low birth weight and its importance in infant health (infant
mortality) is under scrutiny. A review by Wilcox (2001), rebukes that the proportion of births
under 2,500 gram in a population automatically reflects the same risk of infant mortality. His
alternative is based on the fact that some populations (for example, infants born at a higher
elevation) have an overall reduction in birth weight, though the risk of infant mortality does not
increase. Setting the same weight-cutoff which defines increased risk to the infant to one
population at sea-level and one at 6,000 feet, would assign a unnecessarily greater risk to those
infants born at elevation. It is the increased elevation that has shifted the entire birth weight
distribution to the lower end, but this is done without a change in the infant mortality rate of the
population. His proposal for assessing a population at risk is the not the percent of infants born
under 2,500 grams; instead an examination of the ‘residual’ portion of a population’s birth
weight distribution. On a large scale, birth weight is normally distributed, with an extended tail
on the left, which encompasses the IUGR and LBW/pre-term births. These infants outside the
predominate distribution (defined by mean and standard deviation) are the residual population. It
the percent of births in the residual portion of the birth weight distribution that should be the
index for infant risk. He explains that defining a birth weight with increased risk within a
population is plausible. However, between populations, that same weight may not be an accurate
measure of infant mortality risk.
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In regards to Hamilton County, the coinciding LBW incidence and infant mortality
supports that there is an increased risk of infant mortality below the 2,500 gram weight.
However, the analysis that Wilcox proposed would no doubt be interesting to investigate. In the
end, he does stress the importance and strong predictive measurements the birth weight implies,
however, the definition of the LBW classification is in need of re-evaluation.
A continued investigation into the dynamic relationship between fetal programming, the
developmental origin of adult disease, and the 11β-HSD mediated balance of glucocorticoid
production during gestation is highly warranted. If indeed a reduced placental expression of
11β-HSD2 affects the growth potential of infants, longitudinal studies linking expression and
adult disease should be initiated and additional studies on the characterization of common animal
models should be continued.
11β-HSD2 as a Screening Tool for Infants at Risk
The role of 11β-HSD2 in a healthy pregnancy is scientifically well supported. There is
evidence to support that the molecular mechanism of reduced fetal growth is connected to the
balance of cortisol exposure in utero; there must be enough to ensure organ maturation, but not
enough to abate fetal growth.

This makes 11β-HSD type 2 an important endpoint when

investigating high incidences of LBW births. Since in the majority of cases the placenta is
discarded after delivery, molecular examination of this organ in assessing fetal health would
eliminate the need for more invasive collection procedures, such as collection of cord blood.
The utility of 11β-HSD2 activity measurement in a clinical setting has yet to be
determined. These data presented here supports a correlation between expression and fetal
growth, but the association is far from causational. The factors that control its expression are
complex and greatly beyond the scope of this study, but if indeed this enzyme were to be used as
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a screening tool, those factors may have to be controlled for in order to fully assess the risk
associated with a decrease of expression. Although expression begets activity, activity reduction
can also occur independent of expression. Thus, it would have to be determined whether
expression or activity would make a better endpoint for assessment. Several of the studies
concerning the regulation of this enzyme considered both in order to determine whether a
decrease in activity was due to reduced expression, or due to a physical disruption of the enzyme
itself. With the advent of qRT-PCR, expression evaluation is easier and faster than activity
would be, especially when activity is concentrated in the microsomal portion. But enzyme
activity is directly responsible for the in utero exposure to the fetus, this would be a more
relevant, albeit more labor intensive, end point for infant risk.

Environmental contaminants and pregnancy outcomes
Additional environmental factors should be considered when studying fetal or child
health. Ambient air pollution has been shown to affect birth weight (Bell et al., 2007; Bobak,
2000). Chemicals detected in cord blood, such as polychlorinated biphenyls (PCBs) (Murphy et
al., 2009) and Perfluorinated Chemicals (Apelberg et al., 2007) have also been correlated with
reduced birth weight. Other pregnancy complications (preterm labor) have been linked to the
predominate DDT metabolite, DDE (Longnecker et al., 2001).
Domestically, the environmental effects of growth, development, and health of children
will be examined through The National Children’s Study, which was created through the
Children’s Health Act of 2000 (http://www.nationalchildrensstudy.gov/Pages/default.aspx). Not
only will the study report on numerous environmental variables (air and water quality, sound
pollution), but it will also examine what potential effects community, culture and family
structure have on the health of U.S. children through their first 21 years. Increased global
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concern for environmental effects on children brought about the creation of the International
Society for Children’s Health and the Environment, which aims to bring together the many
disciplines that study and play a part in children’s health, from policy makers to analytical
chemists to public health practitioners (Bellinger et al., 2011).
The present study shows that in uncomplicated pregnancies, the growth potential of an
infant positively correlates with placental expression of the 11β-HSD2.

This finding is

consistent with the hypothesis that a reduction in placental 11β-HSD2, leads to a reduced
oxidation of active cortisol to inactive cortisone before passage into the fetus. Without this
cortisol inactivation, an elevated cortisol level in the fetus leads to deleterious programming
before birth, which could result in reduced growth and increased risk of adult diseases, such as
Type-2 diabetes and hypertension.
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CHAPTER 6
CONCLUSION

The current study expands research into the hypothesis that an over-exposure to cortisol
in utero can negatively affect proper fetal growth. The passage of maternal cortisol into the
fetus, via the placenta, is modulated by the enzyme, 11β-hydroxysteroid dehydrogenase type 2.
To date, this is the largest study of its kind to look at this enzyme’s expression over a large
population and it’s relation to the growth potential of a fetus. A significant positive correlation
between 11β-HSD2 and a calculated birth weight centile for non-complicated pregnancies was
found (p = 0.024). Only after confounding maternal and infant factors were controlled for did a
correlation of fetal growth potential and placental expression of 11β-HSD2 occur. Continued
molecular characterization of the placenta, and increased understanding of the critical functions
the placenta performs, is warranted. Deciphering how deleterious pregnancy outcomes are
linked to improper placental function could result in diagnostic tests designed to determine
potential disease risk factors for childhood or adult life. Molecular assessments of the placenta,
coupled with longitudinal studies of specific endpoints of adult health, would help define to what
extent the intrauterine environment plays into the lifespan of an individual.
Significant differences in birth weight were found between Caucasians and African
American mothers, single and married mothers and underweight vs. obese mothers. Without an
accompanying difference of 11β-HSD2 expression suggests that this enzyme did not influence
these differences in birth weight. Further studies could be conducted to deduce whether there is
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an accompanying molecular cause to this difference in BW, in addition to potential
socioeconomic factors.
Despite the potential flaw of the LBW definition, evidence supports that birth weight
can be a predictor of adult health. However, further research into additional molecular endpoints
hold promise to understanding, and ultimately preventing, this pathological reduction of fetal
growth in Hamilton County.

Successful suppression of Hamilton County’s high rate of

pathologically small infants requires further study.

Certainly interdisciplinary, community-

focused programs like BLUES, Centering Pregnancy (https://www.centeringhealthcare.org) and
Infant Mortality Reduction Initiative (Featherstone, 2010) are aiding to curb this LBW trend and
reduced infant mortality. However, when considering the industrial past of this area, and the
areas of Hamilton County of greatest LBW incidence, it is plausible to consider these long lived
contaminates in the soil as a possible confounding variable in the LBW equation.
contaminates, particularly metals,
mechanism

of

restricted

These

are of concern to those interested in deciphering the
fetal

growth
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